Matches in Wikidata for { <http://www.wikidata.org/entity/Q64642647> ?p ?o ?g. }
Showing items 1 to 90 of
90
with 100 items per page.
- Q64642647 description "clinical trial" @default.
- Q64642647 description "ensayu clínicu" @default.
- Q64642647 description "klinisch onderzoek" @default.
- Q64642647 description "клінічне випробування" @default.
- Q64642647 name "A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment." @default.
- Q64642647 type Item @default.
- Q64642647 label "A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment." @default.
- Q64642647 prefLabel "A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment." @default.
- Q64642647 P1132 Q64642647-3BD02F8B-D56F-4726-A014-CA6C4F0DA882 @default.
- Q64642647 P1476 Q64642647-7B9D05A2-6C67-446C-8423-AA466588E5B8 @default.
- Q64642647 P17 Q64642647-039F63E9-07DE-4A23-9579-BE5F87343F42 @default.
- Q64642647 P17 Q64642647-07F20701-8812-4542-8B93-6EDD4690F8A0 @default.
- Q64642647 P17 Q64642647-0E17D1A7-8FDD-4FEB-AFC4-824952BCF0FA @default.
- Q64642647 P17 Q64642647-13FD8B58-0074-4775-9441-E1B0F28EDE77 @default.
- Q64642647 P17 Q64642647-16160839-835F-471F-AA45-33EFE7FDE88F @default.
- Q64642647 P17 Q64642647-1C6304C8-6DCB-4B09-AF7A-A051C3B6E561 @default.
- Q64642647 P17 Q64642647-2D76646B-2A17-4016-AABA-95AE469F0F66 @default.
- Q64642647 P17 Q64642647-3344D6E7-5FCA-4237-BEB2-200CBC804CD3 @default.
- Q64642647 P17 Q64642647-3857E903-C90D-4FEF-8285-87CD0CF6399B @default.
- Q64642647 P17 Q64642647-43BE47E5-2047-40C1-AD93-4A3017F12BF8 @default.
- Q64642647 P17 Q64642647-46C6F68D-225F-459A-96DC-7B7D8846A5DB @default.
- Q64642647 P17 Q64642647-4BB9DCFF-581B-490B-8522-C518B9C67BD8 @default.
- Q64642647 P17 Q64642647-4EF2834A-03A0-47A0-A002-00D95A41DA35 @default.
- Q64642647 P17 Q64642647-677BC24B-05ED-41BA-A14D-11A96B03A5E4 @default.
- Q64642647 P17 Q64642647-7C4B1C94-0A5D-41EC-8C53-FF14002D3FD3 @default.
- Q64642647 P17 Q64642647-849A7FD7-D3D9-45E0-8966-EC2FFF65D917 @default.
- Q64642647 P17 Q64642647-85A2947E-35C1-4CFB-AF1C-B51C2C899C86 @default.
- Q64642647 P17 Q64642647-8917783E-FAEF-4BDC-8352-BD8EB580BD5E @default.
- Q64642647 P17 Q64642647-A36C6F07-7B5E-4F14-99C9-5D80F812F79C @default.
- Q64642647 P17 Q64642647-A98487CC-E270-4008-8623-34870FBA470A @default.
- Q64642647 P17 Q64642647-B2B9F324-9FE2-4DB6-A085-155ED1B81B8E @default.
- Q64642647 P17 Q64642647-C70BF5D3-F1D3-44CE-B696-A82A8CF88962 @default.
- Q64642647 P17 Q64642647-D2C4220D-B4B0-44AF-98E0-E91AD3F6DE73 @default.
- Q64642647 P17 Q64642647-DD39191E-1213-45AF-A0EC-B616978E43B4 @default.
- Q64642647 P17 Q64642647-E2BE776A-1EE1-4A2A-9676-4A8F9C4DC28F @default.
- Q64642647 P17 Q64642647-E34208E3-A061-4FAD-A119-42B6558FA987 @default.
- Q64642647 P17 Q64642647-EA278426-56AF-405A-AF1D-A00CEEEAE628 @default.
- Q64642647 P17 Q64642647-EE457C43-0906-4E82-8E1F-A66299516A32 @default.
- Q64642647 P17 Q64642647-F6248AEA-2F91-4847-95AF-DEF3FCDB7263 @default.
- Q64642647 P17 Q64642647-F8BC646D-074F-45B9-B920-14B5E52037E7 @default.
- Q64642647 P17 Q64642647-FC7994FD-EC41-47C3-8A50-F6A3C88246C7 @default.
- Q64642647 P1813 Q64642647-BA81C5CF-5664-445F-BA3B-80FB0FBA09F1 @default.
- Q64642647 P2899 Q64642647-9FF76415-AEED-46B7-B796-823F5A212B26 @default.
- Q64642647 P3098 Q64642647-82CF5423-3A75-4702-AB2B-8E7D07B5890A @default.
- Q64642647 P31 Q64642647-E49720CB-D9B6-405E-AD11-7A3A1841D726 @default.
- Q64642647 P580 Q64642647-136E51BE-BE46-4C90-8DC8-3B9E7B368455 @default.
- Q64642647 P582 Q64642647-A03CD659-33C4-4D57-BDAE-3A4CEEBA71C3 @default.
- Q64642647 P6099 Q64642647-F6F37418-3ABD-46BB-BEFF-367F2846BCCB @default.
- Q64642647 P8363 Q64642647-516E0616-39F2-49AC-841E-8C31395991AC @default.
- Q64642647 P1132 "+1887" @default.
- Q64642647 P1476 "A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy" @default.
- Q64642647 P17 Q142 @default.
- Q64642647 P17 Q145 @default.
- Q64642647 P17 Q16 @default.
- Q64642647 P17 Q183 @default.
- Q64642647 P17 Q184 @default.
- Q64642647 P17 Q20 @default.
- Q64642647 P17 Q211 @default.
- Q64642647 P17 Q212 @default.
- Q64642647 P17 Q214 @default.
- Q64642647 P17 Q215 @default.
- Q64642647 P17 Q219 @default.
- Q64642647 P17 Q230 @default.
- Q64642647 P17 Q232 @default.
- Q64642647 P17 Q27 @default.
- Q64642647 P17 Q28 @default.
- Q64642647 P17 Q29 @default.
- Q64642647 P17 Q31 @default.
- Q64642647 P17 Q33 @default.
- Q64642647 P17 Q34 @default.
- Q64642647 P17 Q35 @default.
- Q64642647 P17 Q36 @default.
- Q64642647 P17 Q37 @default.
- Q64642647 P17 Q38 @default.
- Q64642647 P17 Q39 @default.
- Q64642647 P17 Q399 @default.
- Q64642647 P17 Q40 @default.
- Q64642647 P17 Q41 @default.
- Q64642647 P17 Q43 @default.
- Q64642647 P17 Q45 @default.
- Q64642647 P17 Q55 @default.
- Q64642647 P17 Q822 @default.
- Q64642647 P1813 "BEYOND" @default.
- Q64642647 P2899 "+18" @default.
- Q64642647 P3098 "NCT01638000" @default.
- Q64642647 P31 Q30612 @default.
- Q64642647 P580 "2012-06-12T00:00:00Z" @default.
- Q64642647 P582 "2013-04-24T00:00:00Z" @default.
- Q64642647 P6099 Q42824827 @default.
- Q64642647 P8363 Q78089383 @default.